V. Bhoj
Immunology · 2009–2018
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 31 citations into it
- Molecular Biology — 25 citations into it
- Cancer Research — 19 citations into it
Whom V. Bhoj trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts V. Bhoj overall
Papers from V. Bhoj's perspective
Ordered by how strongly the researchers V. Bhoj trusts endorse each paper. Same corpus, a different order for every researcher.
- TAK1 is a ubiquitin-dependent kinase of MKK and IKK (Nature)
- Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. (Science)
- Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. (Cancer Cell)
- Innate immune recognition. (Annual Review of Immunology)
- The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. (Molecules and Cells)
- cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. (Molecules and Cells)
- The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. (Cell)
- TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. (Molecules and Cells)
- The Kinase Activity of Rip1 Is Not Required for Tumor Necrosis Factor-α-induced IκB Kinase or p38 MAP Kinase Activation or for the Ubiquitination of Rip1 by Traf2* (Journal of Biological Chemistry)
- Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. (Molecules and Cells)
Their papers
- Ubiquitylation in innate and adaptive immunity (2009) — 633 citations
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell (2018) — 595 citations
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas (2017) — 1,558 citations
- Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease (2016) — 663 citations